Synthetic Membrane-Receiver Complexes
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 5 of these applications claim priority to application 14/738,414, filed Jun 12, 2015. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Patent lifetimeUsedRemaining | Confidence |
|---|---|---|---|---|---|---|
| US 10,253,296 | Synthetic Membrane-Receiver Complexes In force · Medium confidence UsedRemaining | Rubius Therapeutics, Inc. | In force | Medium confidence | ||
| US 10,301,593 | Synthetic Membrane-Receiver Complexes In force · Medium confidence | Rubius Therapeutics, Inc. | In force | Medium confidence | ||
| US 10,301,594 | Synthetic Membrane-Receiver Complexes In force · High confidence | Rubius Therapeutics, Inc. | In force | High confidence | ||
| US 10,329,531 | Synthetic Membrane-Receiver Complexes In force · High confidence | Rubius Therapeutics, Inc. | In force | High confidence | ||
| US 10,344,263 | Synthetic Membrane-Receiver Complexes In force · High confidence | Rubius Therapeutics, Inc. | In force | High confidence | ||
| US 10,557,119 | Erythroid Cells Comprising Phenylalanine Ammonia Lyase Lapsed Feb 11, 2024 on the fee record Medium confidence | Rubius Therapeutics, Inc. | Lapsed Feb 11, 2024 on the fee record | Medium confidence | ||
| US 9,644,180 | Synthetic Membrane-Receiver Complexes Lapsed May 9, 2025 on the fee record Medium confidence | Rubius Therapeutics, Inc. | Lapsed May 9, 2025 on the fee record | Medium confidence | ||
| Application 14/581,486 | Synthetic Membrane-Receiver Complexes Abandoned Abandoned Feb 14, 2017 | Rubius Therapeutics, Inc. | Abandoned | Abandoned Feb 14, 2017 | ||
| Application 15/157,006 | Genetically Engineered Enucleated Erythroid Cells Comprising a Phenylalanine Ammonia Lyase Receiver Polypeptide Abandoned Abandoned Jan 22, 2019 | Rubius Therapeutics, Inc. | Abandoned | Abandoned Jan 22, 2019 | ||
| Application 15/899,895 | Erythroid Cells Comprising Uricase Abandoned Abandoned Jun 17, 2022 | Rubius Therapeutics, Inc. | Abandoned | Abandoned Jun 17, 2022 | ||
| 10 more records in this group · Pro | ||||||
10 of 20 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Pro members see all 20, including 2 expired.
5 of these are in force and held by Rubius Therapeutics, Inc..
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.